key: cord-0783529-outu5o0s
authors: Denorme, Frederik; Manne, Bhanu Kanth; Portier, Irina; Petrey, Aaron C.; Middleton, Elizabeth A.; Kile, Benjamin T.; Rondina, Matthew T.; Campbell, Robert A.
title: COVID‐19 patients exhibit reduced procoagulant platelet responses
date: 2020-10-06
journal: J Thromb Haemost
DOI: 10.1111/jth.15107
sha: bcb57dcba82093d8597ef02a2ca21ab25ebbe06c
doc_id: 783529
cord_uid: outu5o0s

BACKGROUND: Emerging evidence implicates dysfunctional platelet responses in thrombotic complications in COVID‐19 patients. Platelets are important players in inflammation‐induced thrombosis. In particular, procoagulant platelets support thrombin generation and mediate thromboinflammation. OBJECTIVES: To examine if procoagulant platelet formation is altered in COVID‐19 patients and if procoagulant platelets contribute to pulmonary thrombosis. PATIENTS/METHODS: Healthy donors and COVID‐19 patients were recruited from the University of Utah Hospital System. Platelets were isolated and procoagulant platelet formation measured by annexin V binding as well as mitochondrial function were examined. We utilized mice lacking the ability to form procoagulant platelets (CypD(plt−/−)) to examine the role of procoagulant platelets in pulmonary thrombosis. RESULTS AND CONCLUSIONS: We observed that platelets isolated from COVID‐19 patients had a reduced ability to become procoagulant compared to those from matched healthy donors, as evidenced by reduced mitochondrial depolarization and phosphatidylserine exposure following dual stimulation with thrombin and convulxin. To understand what impact reduced procoagulant platelet responses might have in vivo, we subjected mice with a platelet‐specific deletion of cyclophilin D, which are deficient in procoagulant platelet formation, to a model of pulmonary microvascular thrombosis. Mice with platelets lacking cyclophilin D died significantly faster from pulmonary microvascular thrombosis compared to littermate wild‐type controls. These results suggest dysregulated procoagulant platelet responses may contribute to thrombotic complications during SARS‐CoV‐2 infection.

Patients/Methods: Healthy donors and COVID-19 patients were recruited from the University of Utah Hospital System. Platelets were isolated and procoagulant platelet formation measured by annexin V binding as well as mitochondrial function were examined. We utilized mice lacking the ability to form procoagulant platelets (CypD plt−/− ) to examine the role of procoagulant platelets in pulmonary thrombosis.

We observed that platelets isolated from COVID-19 patients had a reduced ability to become procoagulant compared to those from matched healthy donors, as evidenced by reduced mitochondrial depolarization and phosphatidylserine exposure following dual stimulation with thrombin and convulxin.

To understand what impact reduced procoagulant platelet responses might have in vivo, we subjected mice with a platelet-specific deletion of cyclophilin D, which are deficient in procoagulant platelet formation, to a model of pulmonary microvascular thrombosis. Mice with platelets lacking cyclophilin D died significantly faster from pulmonary microvascular thrombosis compared to littermate wild-type controls.

These results suggest dysregulated procoagulant platelet responses may contribute to thrombotic complications during SARS-CoV-2 infection.

Thrombotic complications are common in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [1] [2] [3] In particular, intravascular pulmonary thrombosis is believed to contribute to acute respiratory distress syndrome (ARDS) and mortality in COVID-19 patients. 4 Previously, we demonstrated that neutrophil extracellular traps (NETs) and platelets accumulate in the lung microvasculature of COVID-19 patients. 5 Furthermore, platelets from COVID-19 patients were hyperresponsive to agonist stimulation and interacted more with leukocytes at baseline, indicating crosstalk between platelets and leukocytes during SARS-CoV-2 infection. 6 Upon strong activation by classical agonists, a subpopulation of platelets becomes procoagulant. These procoagulant platelets have distinct properties, including the ability to support thrombin generation, an increased tendency to interact with leukocytes, and a reduced capacity to aggregate. 7 Recently, we and others described a critical role for procoagulant platelets in the formation of detrimental platelet--neutrophil aggregates during reperfusion injury. 8, 9 Interestingly, in septic patients, 10 as well as patients infected with human immunodeficiency virus (HIV) 11 patient or healthy donor, we collected ~60 mL of anticoagulant citrate dextrose (ACD)-anticoagulated whole blood via venipuncture for assays described below. 

For all analyses, continuous variables were assessed for normality with skewness and kurtosis tests. Summary statistics were used to describe the study cohort and clinical variables are expressed as the mean ± standard deviation or as a number and percentage (%). Parametric two-tailed t-tests or analysis of variance were used for continuous variables. Statistical analyses were performed by using GraphPad Prism (version 7, San Diego, CA). A two-tailed P-value < .05 was considered statistically significant. Figure 1A-B) . Procoagulant platelet responses were similarly reduced in non-intensive care unit (ICU) and ICU patients (P = .7, Figure 1B ) and did not correlate with disease severity (data not shown). In contrast, platelets from healthy donors and COVID-19 patients stimulated with the Ca 2+ ionophore A23187 displayed similar levels of PS exposure ( Figure 1C-D) . The latter result suggests that reduced procoagulant platelet responses observed in COVID-19 patients are likely not due to defective or impaired PS scramblase activity. 17, 18 Formation of the mitochondrial permeability transition pore is a critical event in the generation of procoagulant platelets 19, 20 and results in a decrease in mitochondrial membrane potential and the subsequent release of mitochondrial Ca 2+ initiating PS exposure.

To investigate whether dysfunction of the mitochondrial permeability transition pore contributes to our observations in COVID-19 bind coagulation factors, they also have a reduced ability to aggregate. 26 In particular, CypD-dependent procoagulant platelet formation initiates a negative-feedback mechanism that limits platelet aggregation and subsequent thrombosis. 24 The reduced ability to form procoagulant platelets in COVID-19 patients could therefore potentially result in hyper-aggregating platelets, as previously described. 6 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series

Neutrophil extracellular traps (NETs) contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Platelet gene expression and function in COVID-19 patients

Procoagulant platelets: generation, function, and therapeutic targeting in thrombosis

Neutrophil macroaggregates promote widespread pulmonary thrombosis after gut ischemia

Platelet necrosis mediates ischemic stroke outcome in mice

Phosphatidylserine-mediated platelet clearance by endothelium decreases platelet aggregates and procoagulant activity in sepsis

Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection

Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets

Autopsy findings and venous thromboembolism in patients with COVID-19

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Mitochondrial calcium and reactive oxygen species regulate agonist-initiated platelet phosphatidylserine exposure

TMEM16F forms a Ca2+-activated cation channel required for lipid scrambling in platelets during blood coagulation

Role of mitochondrial permeability transition pore in coated-platelet formation

Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis

TMEM16F is required for phosphatidylserine exposure and microparticle release in activated mouse platelets

Inner mitochondrial membrane disruption links apoptotic and agonist-initiated phosphatidylserine externalization in platelets

Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo

Mitochondrially mediated integrin αIIbβ3 protein inactivation limits thrombus growth

Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow

Platelet-based coagulation: different populations, different functions

Postoperative deep venous thrombosis after renal transplantation. Effects of cyclosporine

Platelet cyclophilin D-dependent events limit venous thrombotic occlusion and platelet accretion

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

COVID-19 patients exhibit reduced procoagulant platelet responses

The authors wish to acknowledge figure preparation expertise from Diana Lim and assistance with participant recruitment from Antoinette Blair, Macy Barrios, Amber Plante, Jordan Greer, Amy DeNardo, Amanda Bailey, and Lindsey Waddoups.